.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Merck
Novartis
Daiichi Sankyo
Dow
Deloitte
Julphar
Fuji
Farmers Insurance
Argus Health

Generated: September 21, 2017

DrugPatentWatch Database Preview

FULYZAQ Drug Profile

« Back to Dashboard

What is the patent landscape for Fulyzaq, and when can generic versions of Fulyzaq launch?

Fulyzaq is a drug marketed by Napo Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-four patent family members in twenty-one countries.

The generic ingredient in FULYZAQ is crofelemer. Two suppliers are listed for this compound. Additional details are available on the crofelemer profile page.

Summary for Tradename: FULYZAQ

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Drug Prices:see details
DailyMed Link:FULYZAQ at DailyMed

Pharmacology for Tradename: FULYZAQ

Drug ClassAntidiarrheal
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Napo Pharms Inc
FULYZAQ
crofelemer
TABLET, DELAYED RELEASE;ORAL202292-001Dec 31, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FULYZAQ

Country Document Number Estimated Expiration
Spain2326933► Subscribe
Australia775330► Subscribe
Brazil112013010774► Subscribe
European Patent Office2255661► Subscribe
European Patent Office0935417► Subscribe
Japan2017019806► Subscribe
World Intellectual Property Organization (WIPO)2012058664► Subscribe
Mexico2013004873► Subscribe
Russian Federation2013123794► Subscribe
Russian Federation2597746► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
McKinsey
Argus Health
Boehringer Ingelheim
Covington
Moodys
Deloitte
Johnson and Johnson
Novartis
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot